Xiaoyan Li
Research Subjects
Research Interests
Xiaoyan Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Qifeng Yang
Department of Breast Surgery, Qilu Hospital of Shandong University, Ji’nan, China
2 shared publications - Bing Chen
Pathology Tissue Bank, Qilu Hospital of Shandong University, Ji’nan, Shandong, China
1 shared publication - Lijuan Wang
Biological Resource Center, Qilu Hospital of Shandong University, Jinan, China
1 shared publication Liyu Jiang
Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, China
1 shared publication- Ning Zhang
Department of Breast Surgery General Surgery Qilu Hospital of Shandong University Ji'nan China
1 shared publication Sisi Chen
Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 27 September 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-9
Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
Objectives. Molecular subtypes are employed as a guide for targeted treatment and important prognostic factors. This study focused on investigating the association of serum levels of CEA, CA15-3, and CA125 with clinicopathological characteristics of breast cancer to find prognostic markers for breast cancer and provide precise targeted therapy. Materials and Methods. In this study, 961 breast cancer patients with preoperative serum levels of CEA, CA15-3, and CA125 and molecular subtypes were analyzed. Cut-off values of 5 ng/ml, 25 U/ml, and 35 U/ml were used for CEA, CA15-3, and CA125, respectively. The 2 test and Fisher exact test along with logistic multivariate regression analysis were performed for investigating the correlation of CEA, CA15-3, and CA125 serum levels with molecular subtypes and associated factors. Results. An increase in the serum concentrations of CEA, CA15-3, and CA125 was discovered in 48 (4.99%), 54 (5.62%), and 55 (5.72%) breast cancer patients, respectively. Univariate analysis demonstrated that the levels of CEA ( ) and CA15-3 ( ) were significantly linked with molecular types of breast cancer. Moreover, patients having larger tumor size ( , , and , respectively) along with nodal metastasis ( , , and , respectively) exhibited higher rates of elevated CEA, CA15-3, and CA125 levels. Status of Her-2 positive ( ) had a significant connection with elevated CEA levels. Multivariate analysis further indicated that molecular subtypes were independent factors associated with CEA and CA15-3 levels. Also, Her-2 status was significantly and independently related to CEA levels. Conclusion. Preoperative serum levels of CEA and CA15-3 were independently associated with molecular subtypes of breast cancer. CEA and CA15-3 might improve the prognostic prediction for patients with breast cancer and inform the selection of specific therapies. A further biological analysis is needed for investigating the relationship between Her-2 expression and CEA levels.
- 27 September 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-9
Open AccessAssociation of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
Objectives. Molecular subtypes are employed as a guide for targeted treatment and important prognostic factors. This study focused on investigating the association of serum levels of CEA, CA15-3, and CA125 with clinicopathological characteristics of breast cancer to find prognostic markers for breast cancer and provide precise targeted therapy. Materials and Methods. In this study, 961 breast cancer patients with preoperative serum levels of CEA, CA15-3, and CA125 and molecular subtypes were analyzed. Cut-off values of 5 ng/ml, 25 U/ml, and 35 U/ml were used for CEA, CA15-3, and CA125, respectively. The 2 test and Fisher exact test along with logistic multivariate regression analysis were performed for investigating the correlation of CEA, CA15-3, and CA125 serum levels with molecular subtypes and associated factors. Results. An increase in the serum concentrations of CEA, CA15-3, and CA125 was discovered in 48 (4.99%), 54 (5.62%), and 55 (5.72%) breast cancer patients, respectively. Univariate analysis demonstrated that the levels of CEA ( ) and CA15-3 ( ) were significantly linked with molecular types of breast cancer. Moreover, patients having larger tumor size ( , , and , respectively) along with nodal metastasis ( , , and , respectively) exhibited higher rates of elevated CEA, CA15-3, and CA125 levels. Status of Her-2 positive ( ) had a significant connection with elevated CEA levels. Multivariate analysis further indicated that molecular subtypes were independent factors associated with CEA and CA15-3 levels. Also, Her-2 status was significantly and independently related to CEA levels. Conclusion. Preoperative serum levels of CEA and CA15-3 were independently associated with molecular subtypes of breast cancer. CEA and CA15-3 might improve the prognostic prediction for patients with breast cancer and inform the selection of specific therapies. A further biological analysis is needed for investigating the relationship between Her-2 expression and CEA levels.
- 6 June 2019
- Published by Wiley in The Breast Journal
- Vol. 25 (5) , 1025-1028
Enlarged para‐sentinel lymph node dissection is not necessary in breast cancer patients undergoing sentinel lymph node biopsy
- 6 June 2019
- Published by Wiley in The Breast Journal
- Vol. 25 (5) , 1025-1028
Enlarged para‐sentinel lymph node dissection is not necessary in breast cancer patients undergoing sentinel lymph node biopsy